Market evolution: Enzymes (CN 3507) — 2015–2025

Introduction

This report examines the European Union's trade in enzymes and prepared enzymes (Customs heading 3507) over the period 2015–2025. The analysis draws on trade flows between the EU and non-EU countries, covering value, volume, and unit-price dynamics across the two sub-headings that compose CN 3507: rennet and concentrates thereof (350710) and all other enzymes and prepared enzymes not elsewhere specified (350790). Over the decade, the EU consolidated its position as a major net exporter of enzymes, with trade values rising substantially faster than traded volumes — a pattern that reflects both structural shifts in the industry and the pricing pressures that emerged after 2020. The report is organised around three central findings: the price-driven expansion of the EU's trade surplus, the realignment of partner-country relationships, and the growing depth and integration of the European production base.

General overview

1. A Widening Surplus Driven More by Rising Prices Than by Expanding Volumes

The EU's trade surplus in enzymes grew from €1.08 billion in 2015 to €1.56 billion in 2025, an increase of 44.2%. However, the underlying dynamics reveal that this expansion owed far more to pricing gains than to volume growth, a distinction that is critical for understanding the market's trajectory.

Export values grew at nearly four times the rate of export volumes

EU exports rose from €1.52 billion to €2.24 billion (+47.1% in value) over the period, while exported quantities increased only from 136,333 tonnes to 153,159 tonnes (+12.3%). The average export unit price climbed from €11,150/t to €14,607/t (+31.0%), meaning that roughly two-thirds of the value expansion can be attributed to higher prices rather than greater throughput. The peak in both value and volume occurred in 2022, when exports reached €2.28 billion and 160,171 tonnes respectively, before easing modestly in subsequent years.

Imports tell a starker story: value surged while volumes were essentially flat

EU imports of enzymes increased from €440 million to €680 million (+54.5% in value), yet the imported quantity barely moved — from 45,736 tonnes to 45,643 tonnes (−0.2%). The import unit price thus rose from €9,580/t to €14,854/t (+55.0%), the single largest proportional increase among the headline metrics. This indicates that the EU's growing import bill was driven entirely by price inflation rather than by rising physical demand for foreign enzymes.

The sub-heading breakdown confirms the dominance of industrial enzymes

The bulk of both trade flows resides in sub-heading 350790 (enzymes excluding rennet). In 2025, this sub-heading accounted for 97.4% of total export value (€2.17 billion) and 99.3% of total import value (€675 million). Rennet (350710) remained a niche product: its export value reached only €64.6 million and import value €4.4 million in 2025. Notably, the unit price of imported rennet fell from €8,147/t to €5,275/t (−35.3%) over the period, contrasting with the general upward trend for industrial enzymes.

Trade overview

2. Partner Realignment: Rising Concentration on the Import Side and Diversification on the Export Side

The geographic composition of EU enzyme trade shifted markedly between 2015 and 2025. On the import side, the United States and China grew in dominance while the United Kingdom receded, driving the Herfindahl–Hirschman Index (HHI) for import concentration above the 2,500 threshold typically associated with high concentration. On the export side, by contrast, the EU diversified its customer base, lowering the HHI and expanding into fast-growing emerging markets.

The United States and China consolidated their positions as top import suppliers

The United States remained the EU's largest source of enzyme imports throughout the period, with import value nearly doubling from €155 million to €307 million (+98.0%). China's share grew even faster — from €67 million to €133 million (+100.5%) — making it the second-largest supplier. Together, these two countries accounted for a growing share of the EU import bill. India also emerged as a significant supplier, with imports surging from €12 million to €29 million (+146.7%).

The United Kingdom's decline as an import partner is notable

The UK's share of EU enzyme imports fell from €54 million in 2015 to €29 million in 2025 (−46.5%), making it the only major partner to register a significant absolute decline. This trend is consistent with the post-Brexit reconfiguration of EU–UK supply chains, though the enzyme market may have also been affected by shifts in the UK's own production capacity.

The import-side HHI crossed into the "highly concentrated" range

The value-based HHI for EU enzyme imports rose from 1,958 to 2,811 (+43.6%), moving from moderate to high concentration. By volume, the HHI also increased — from 3,108 to 3,665 (+17.9%). This growing concentration on the supply side introduces structural vulnerability: a disruption affecting US or Chinese production would now have a larger impact on EU import flows than it would have a decade ago.

EU export destinations became more diversified

In contrast to the import side, the export HHI fell from 1,021 to 858 (−16.0% by value), indicating a broadening of the EU's customer base. Türkiye emerged as a major growth market, with EU exports surging from €78 million to €151 million (+95.2%). India saw the fastest proportional growth among major destinations: EU exports to India grew from €31 million to €87 million (+175.4%). Brazil also expanded strongly, from €82 million to €146 million (+77.2%). Meanwhile, exports to the Russian Federation declined from €76 million to €57 million (−24.5%), a trajectory that accelerated after 2022.

Partner concentration · Top partners

3. A Deepening Production Base and Strengthening Export Integration

Behind the trade figures lies a substantial expansion of the EU's own enzyme production. Domestic output grew both in volume (+76.7%) and especially in value (+168.8%), well outpacing trade growth. This production surge, combined with a high and rising export propensity, confirms that the EU enzyme industry is fundamentally export-oriented and increasingly competitive on global markets. At the same time, price shocks observed in 2021–2022 hint at supply-chain disruptions that affected multiple partners.

EU production of enzymes roughly doubled in both volume and value

According to PRODCOM data, EU production of enzymes (CN 3507) rose from 160.4 million kg in 2015 to 283.3 million kg in 2025 (+76.7%). In value terms, output grew from €970 million to €2.61 billion (+168.8%), implying a sharp increase in average production value per kilogram — consistent with the broader trend of rising unit prices observed in trade data. Production value peaked at €2.98 billion in 2023 before retreating slightly, suggesting some normalisation of post-pandemic pricing.

Denmark dominated EU enzyme exports, but the Netherlands gained the most ground

Denmark's enzyme exports grew from €582 million to €855 million (+46.9%), accounting for roughly 38% of total EU exports in 2025 — a position underpinned by a revealed comparative advantage (RCA) of 16.4, by far the highest in the EU. However, the most striking growth came from the Netherlands, whose exports more than doubled from €167 million to €405 million (+141.6%), propelling it past France and into third place among EU exporters. Lithuania also showed notable dynamism, with exports rising from €22 million to €68 million (+212.7%), though from a smaller base.

EU reporter specialisation · EU reporters

The EU's net-exporter position more than doubled

The EU's net import reliance — measured as net imports relative to apparent consumption — moved from −75.9% to −168.0% over the period. The negative sign indicates a persistent and growing net-exporter status: by 2025, the EU exported nearly 1.7 times as much as it consumed domestically. Concurrently, export propensity (exports as a share of production) rose from 70.4% to 86.1%, indicating that an ever-larger share of EU-manufactured enzymes is destined for foreign markets. Trade intensity also rose, from 76.8% to 88.7%, underscoring the sector's deep integration into global value chains.

Price shocks in 2021–2022 affected key trading relationships

The data reveals several notable price shocks. The most prominent was an EU export price shock to India in 2021, with an abnormality score of 369.7 and a year-on-year price shift of +33.3% — an exceptionally large move. In the same year, EU import prices from China spiked with an abnormality of 22.7 and a +25.3% shift, coinciding with post-pandemic supply-chain disruptions. A secondary shock appeared in 2022 on EU exports to Indonesia, with prices jumping +62.9%. Among regular import partners, volatility (measured by coefficient of variation) was highest for Canada (CV = 0.80), Argentina (0.67), and Mexico (0.60), while the US and China showed comparatively low volatility (CV of 0.09 and 0.17 respectively), reinforcing their roles as stable suppliers.

Production volumes

Conclusion

Over the 2015–2025 period, the EU enzyme market (CN 3507) underwent substantial growth, but the nature of that growth was distinctive. Rather than being volume-driven, the expansion of the EU's trade surplus — from €1.08 billion to €1.56 billion — was predominantly a price story: unit values for both exports and imports rose by 31–55%, while traded volumes grew modestly or remained flat. This pricing trend, which accelerated after 2020, likely reflects a combination of product-mix upgrading toward higher-value enzyme preparations, post-pandemic supply-chain cost pressures, and the growing market power of specialised EU producers.

On the structural side, the market presents a dual reality. The EU's domestic production base expanded vigorously (output value nearly tripled), and the bloc's export propensity reached 86%, confirming the enzyme sector as a deeply outward-facing industry anchored by Denmark and increasingly by the Netherlands. At the same time, the concentration of EU imports into fewer supplier countries — principally the United States and China — rose to a level that may warrant attention from a supply-security perspective. The United Kingdom's decline as both an import source and an export destination is a visible consequence of Brexit-era trade restructuring.

Looking forward, the key dynamics to monitor include the sustainability of the post-2020 price levels, the continued diversification (or further concentration) of import sources, and whether emerging export markets such as India, Türkiye, and Brazil will continue to absorb a growing share of EU enzyme output.